Cellectar Biosciences Inc (CLRB) SEC 13F Holdings (Q2 2026): Institutional Buyers & Sellers

CLRB ranks #7558 out of 37701 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

29 institutions disclose a position in CLRB, but none treat it as a major bet — even Empery Asset Management, LP, its most concentrated holder, allocates just 0.6% of its own portfolio to it.

CLRB is up 4.3% today, and institutions have been net buyers of $7.5M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

CLRB reported a net loss of $21.8M in its latest fiscal year.

• Not yet profitable — net loss of $21.8M in the latest fiscal year
• Net income improved year over year, from -$44.6M to -$21.8M
• Operating cash flow was negative, using $23.1M in cash
• Current ratio of 2.96x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.59x equity — within a conventional range